Peptide 101: PT-141 (Bremelanotide)

PT-141 (bremelanotide) is one of the few peptides we cover with a real FDA approval. It treats low sexual desire in premenopausal women by working on the brain's desire circuitry, not blood flow or hormones. Here's the plain-English version — how it works, what the trials actually showed, and the honest trade-offs.

Every issue, we take one peptide and explain it like you're hearing about it for the first time. No biochemistry degree required. So far we've stuck to the metabolic heavy-hitters: semaglutide, tirzepatide, and the recovery-world favorite BPC-157. This week is a hard left turn. PT-141 has nothing to do with weight or healing. It's about desire, and it's one of the very few peptides we cover that carries a real FDA approval and a brand name.

PT-141's proper name is bremelanotide, and it's sold as Vyleesi. In 2019 the FDA approved it for premenopausal women dealing with a frustrating and surprisingly common problem: a real drop in sexual desire that bothers them and isn't explained by a relationship issue, another illness, or a medication. The clinical label for that is hypoactive sexual desire disorder, or HSDD. Bremelanotide was the first on-demand treatment approved for it, and it still has the field mostly to itself. You take it as a small under-the-skin injection from a pen-style auto-injector, about 45 minutes before sex, up to eight times a month. (It actually started as a spin-off of Melanotan II, a tanning peptide. That family resemblance shows up again later, in the side effects.)

You may have seen it called "the female Viagra." That label is catchy and basically wrong. Viagra works on plumbing — it boosts blood flow so the body's physical response shows up on cue. Bremelanotide doesn't go near blood flow. It works a level up, in the brain, on the circuitry that generates interest in the first place. The two drugs are aimed at completely different parts of the problem. You can have the plumbing working fine and still feel nothing, and that gap is exactly what this drug was built for.

Picture desire as a signal in the brain with a volume knob. Bremelanotide turns the knob up.

A little more precisely: it switches on a set of receptors deep in the brain's reward system (melanocortin-4 receptors, if you want the proper term) that sit just upstream of dopamine, the chemistry of wanting and anticipation. Most other approaches to low desire either adjust hormones or, like the ED pills, work on blood flow. This one ignores both and goes straight for the interest signal. That's an unusual place for a drug to act, and it's the entire reason bremelanotide exists.

Our read on the evidence: strong, at least for the narrow group it's approved for. The approval rests on two large, carefully run trials called RECONNECT, published in 2019. Over six months, premenopausal women with HSDD who used bremelanotide reported more desire and less distress about their lack of it than women given a placebo. The benefit was real and it held up statistically.

It was also modest. This isn't a switch that drops people back into their twenties. Plenty of women in the trials didn't respond at all, and for those who did, the average gain was meaningful rather than dramatic. One more thing worth holding in mind: the studies were paid for by the company that makes the drug. That's completely normal for a new approval, but it's the kind of detail a careful reader keeps in view.

There's an older chapter to the story, too. Long before the women's-health trials, PT-141 was tested in men with erectile dysfunction back in the 2000s, including some who hadn't responded to Viagra. It looked promising, but it pushed blood pressure up enough to spook researchers, and that path was eventually dropped. So when you see PT-141 marketed "for men" today, know that it's investigational. Not approved, and not the settled science that the women's indication is.

The headline risk is nausea. Around four in ten women in the trials felt sick to their stomach, and it's the number-one reason people stop using it. For some it eases with time; for others it's a dealbreaker on its own. Flushing, headache, and a sore spot at the injection site are common too.

Two issues deserve their own spotlight. First, every dose nudges blood pressure up for a little while. It's not enough to bother most healthy people, but it's enough that the drug is off-limits if you have high blood pressure that isn't under control, or a recent heart attack or stroke. Second — and here's that tanning-peptide family resemblance again — repeated use can darken patches of skin, sometimes on the face and even the gums. That same pigment effect is why a history of melanoma or a lot of unusual moles is a reason to stay away.

A few clear reasons to talk it through with a clinician first, or to skip it altogether:

That's not the whole list, and none of it is a dose. The specifics are your prescriber's job.

A few questions come up about this one more than any others:

"Isn't this just Melanotan II?" Not quite. Melanotan II is the older, unapproved tanning peptide people buy gray-market. Bremelanotide is its refined, FDA-approved descendant, retooled to act on desire instead of pigment. They're cousins, which is exactly why the skin-darkening side effect rides along.

"Can men use it?" Not officially. It was tested in men with erectile dysfunction years ago and showed some promise, but the blood-pressure spikes stalled it, and there's no approved product for men today. Anything marketed that way is off-label and unproven.

"Do I take it every day?" No — it's on-demand. You use it before sex, not on a daily schedule, and the label caps how often. That's the main practical difference between it and flibanserin, the daily pill for the same condition.

The honest summary: bremelanotide is a real option for a problem medicine spent decades waving off. It isn't a miracle, and it isn't the "female Viagra" the headlines promised. It's a modest, precisely aimed tool that happens to work on something none of the other treatments reach, and for the right person that can matter a lot. Nothing here is medical advice or a push to go ask for it by name. It's an explainer, full stop, meant to make you a sharper patient when you do talk to someone who knows your history.

— The Editors

About PT-141

PT-141 (Vyleesi) is an FDA-approved prescription medication indicated for: Hypoactive sexual desire disorder in premenopausal women. Any discussion of uses beyond the FDA-approved labeling is for educational purposes only and does not constitute a recommendation for off-label use. PT-141 is a prescription medication that requires a valid prescription from a licensed healthcare provider. Do not attempt to obtain or use this medication without proper medical supervision.

Medical disclaimer

This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.